Quick Summary

Pinellia ternata is a traditional Chinese medicinal herb frequently used as part of multi-herb formulas for various conditions, including lung cancer support, obesity-type polycystic ovary syndrome (PCOS), chronic gastritis, and chemotherapy-related symptoms. Clinical evidence primarily involves its use combined with other herbs within established formulas rather than as a standalone treatment. Evidence from systematic reviews and meta-analyses indicates potential adjunctive benefits in these contexts, although high-quality standalone clinical trials specifically on Pinellia ternata are limited.

What Is It?

Pinellia ternata is a perennial herb commonly used in Traditional Chinese Medicine (TCM). It is typically processed before use to reduce inherent toxicity. The herb is often incorporated into complex herbal formulas targeting diverse health conditions.

Traditional Uses

  • Supportive treatment in lung cancer as part of multi-herb formulas.
  • Management of obesity-type polycystic ovary syndrome (PCOS).
  • Treatment of chronic gastritis and gastrointestinal disorders.
  • Relief of chemotherapy-induced symptoms such as nausea and vomiting.

Active Compounds

Pinellia ternata contains several bioactive compounds, including alkaloids, polysaccharides, and lectins, which are believed to contribute to its therapeutic properties in traditional usage. However, detailed human pharmacokinetic data remain limited.

Potential Benefits with Evidence Levels

  • Adjunctive in Lung Cancer Treatment: Pinellia ternata is a core herb in formulas like modified Yukgunja-tang (Liujunzi Decoction) and Zeqi Decoction used alongside conventional lung cancer therapies, showing improvements in treatment response rates, symptom relief, immune markers, and reduction in treatment toxicity. The evidence level is moderate, based on systematic reviews and meta-analyses of randomized controlled trials (RCTs) using multi-herb formulas containing Pinellia ternata.
  • Obesity-type Polycystic Ovary Syndrome (PCOS): Included in herbal prescriptions combined with Western medicine, Pinellia ternata shows moderate confidence evidence for improving body mass index (BMI), hormone levels, and insulin resistance. This conclusion is supported by network meta-analysis of RCTs involving multi-herb formulas.
  • Functional Gastrointestinal Disorders: Used in classical formulations such as Banxia Xiexin Decoction for chronic gastritis, functional dyspepsia, and chemotherapy-induced nausea and vomiting, with some evidence from meta-analyses supporting efficacy and safety. The evidence level ranges from low to moderate.
  • Adjunctive Treatment for Metabolic and Inflammatory Conditions: Part of formulas targeting metabolic syndrome components, type 2 diabetes, and inflammatory conditions. Evidence suggests potential improvements in clinical outcomes when combined with Western medicine; however, evidence is low to moderate.
  • Chemotherapy-Induced Nausea and Vomiting (CINV): Mentioned among medicinal plants with potential antiemetic, chemosensitizing, and immunomodulatory properties, usually as part of combination therapies rather than a sole agent. Human clinical evidence is currently insufficient.

Side Effects

No specific adverse effects directly linked to Pinellia ternata monotherapy have been identified in clinical research to date. Adverse events reported generally relate to combined herbal formulas or concomitant Western therapies. Traditional knowledge indicates potential toxicity with unprocessed Pinellia, so adequate processing is essential.

Drug Interactions

There is no direct clinical evidence on drug interactions involving Pinellia ternata. Given its frequent use alongside other herbs and Western medications, potential interactions cannot be ruled out and warrant further research and caution.

Who Should Avoid It

  • Individuals with known hypersensitivity to any component in the formulas containing Pinellia ternata.
  • Pregnant or breastfeeding women, due to lack of safety data.
  • People advised to avoid unprocessed Pinellia because of traditional concerns about toxicity.

Evidence Limitations

  • Most clinical evidence involves Pinellia ternata as part of multi-herb preparations rather than isolated use, complicating attribution of effects.
  • Quality of clinical trials is often limited by small sample sizes, lack of blinding, or unclear allocation concealment.
  • Safety data specific to Pinellia ternata monotherapy are scarce.
  • High heterogeneity and methodological weaknesses affect the strength of conclusions.
  • Lack of standardized treatment protocols and dose optimization in studies.
  • Limited data on pharmacokinetics, mechanisms in humans, and long-term outcomes.
  • Insufficient evidence regarding drug interactions and safety in sensitive populations such as pregnant or breastfeeding women.

References

Last Reviewed

April 2024

Disclaimer: This page is for informational purposes only and does not constitute medical advice. Pinellia ternata and related herbal formulas may carry risks and should only be used under the guidance of a qualified healthcare professional. Clinical evidence is evolving, and more high-quality research is needed to clarify efficacy, safety, dosage, and interactions.